Literature DB >> 8877877

Physicochemical characterization of a synthetic lipid emulsion for hepatocyte-selective delivery of lipophilic compounds: application to polyiodinated triglycerides as contrast agents for computed tomography.

D A Bakan1, M A Longino, J P Weichert, R E Counsell.   

Abstract

A synthetic lipid emulsion (LE) has been developed with physicochemical properties that closely resemble those of a specific class of naturally-occurring lipoproteins known as chylomicron remnants. The formulation has the potential to serve as a hepatocyte-selective delivery system for any lipophilic or amphipathic compounds that can be associated with the internal lipid phase of the emulsion. In the present studies, a lipophilic polyiodinated triglyceride (ITG) was successfully incorporated into the delivery vehicle to form a stable chylomicron-remnant-like emulsion capable of localizing material to the liver following intravenous injection. The preferred ITG-LE formulation was shown to have a mean particle diameter of less than 200 nm and a particle size stability profile in excess of 12 months. The viscosity, pH, and osmolality of the formulation also appeared favorable for safe and convenient intravenous injection. The particle size profile, chemical properties, and high degree of incorporation of ITG into the emulsion suggest that the ITG-LE formulation holds substantial promise as a hepatocyte-selective imaging agent for computed tomography of the liver. Biodistribution, elimination, and computed tomography (CT) imaging results in animals corroborated the hepatocyte-selective nature of the ITG-LE formulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8877877     DOI: 10.1021/js960119z

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma.

Authors:  Lucia Martiniova; Susannah Cleary; Edwin W Lai; Dale O Kiesewetter; Jurgen Seidel; Linda F Dawson; Jacqueline K Phillips; David Thomasson; Xiaoyuan Chen; Graeme Eisenhofer; James F Powers; Richard Kvetnansky; Karel Pacak
Journal:  Nucl Med Biol       Date:  2011-09-29       Impact factor: 2.408

2.  Time-course of contrast enhancement in spleen and liver with Exia 160, Fenestra LC, and VC.

Authors:  Inneke Willekens; Tony Lahoutte; Nico Buls; Christian Vanhove; Rudi Deklerck; Axel Bossuyt; Johan de Mey
Journal:  Mol Imaging Biol       Date:  2008-12-06       Impact factor: 3.488

Review 3.  Nanotechnology for computed tomography: a real potential recently disclosed.

Authors:  Nicolas Anton; Thierry F Vandamme
Journal:  Pharm Res       Date:  2013-07-30       Impact factor: 4.200

4.  MicroCT liver contrast agent enhancement over time, dose, and mouse strain.

Authors:  Chris E Suckow; David B Stout
Journal:  Mol Imaging Biol       Date:  2008-01-16       Impact factor: 3.488

Review 5.  Nanoparticle contrast agents for computed tomography: a focus on micelles.

Authors:  David P Cormode; Pratap C Naha; Zahi A Fayad
Journal:  Contrast Media Mol Imaging       Date:  2014 Jan-Feb       Impact factor: 3.161

6.  Noninvasive monitoring of a murine model of metastatic pheochromocytoma: a comparison of contrast-enhanced microCT and nonenhanced MRI.

Authors:  Lucia Martiniova; Melanie S Kotys; David Thomasson; Daniel Schimel; Edwin W Lai; Marcelino Bernardo; Maria J Merino; James F Powers; Jan Ruzicka; Richard Kvetnansky; Peter L Choyke; Karel Pacak
Journal:  J Magn Reson Imaging       Date:  2009-03       Impact factor: 4.813

Review 7.  In vivo micro-CT imaging of liver lesions in small animal models.

Authors:  Lucia Martiniova; Daniel Schimel; Edwin W Lai; Andrea Limpuangthip; Richard Kvetnansky; Karel Pacak
Journal:  Methods       Date:  2009-06-09       Impact factor: 3.608

8.  Micro-CT based experimental liver imaging using a nanoparticulate contrast agent: a longitudinal study in mice.

Authors:  Hanne Boll; Stefanie Nittka; Fabian Doyon; Michael Neumaier; Alexander Marx; Martin Kramer; Christoph Groden; Marc A Brockmann
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.